SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess
Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.
May 29, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Startup ViralClear Drives Antiviral into Phase II for COVID-19 Following Significant Preclinical Results
ViralClear Chief Executive Officer Nick Spring told BioSpace that the preclinical work is “telling a very good story.”
May 28, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Neurotrope and NIH Launch Long-Term Trial of Bryostatin in Alzheimer’s
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
May 28, 2020
 · 
2 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate
The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.
May 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CanSino Publishes Phase I Data for COVID-19 Vaccine Candidate, Moves into Phase II
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 22, 2020
 · 
2 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
 · 
3 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting
January 16, 2026
 · 
3 min read
Press Releases
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus
January 15, 2026
 · 
3 min read
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
 · 
8 min read
Press Releases
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
January 14, 2026
 · 
4 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Press Releases
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
January 13, 2026
 · 
4 min read
Press Releases
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
 · 
2 min read
Press Releases
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
January 13, 2026
 · 
3 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
January 13, 2026
 · 
4 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
January 13, 2026
 · 
7 min read
Press Releases
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 13, 2026
 · 
9 min read
Load More